Keros Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
KROS Nasdaq 2836 www.kerostx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Keros Therapeutics, Inc.

KROS Begins Dosing in Phase II Study With Rinvatercept in DMD - Sep 29th, 2026 7:17 am
Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda - Sep 29th, 2026 6:00 am
Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD - Sep 28th, 2026 6:00 am
Keros Therapeutics Announces $5 Million Share Repurchase Authorization - Sep 8th, 2026 2:01 pm
Why Is Keros Therapeutics (KROS) Up 8% Since Last Earnings Report? - Sep 2nd, 2026 9:30 am
KROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays Weak - Aug 24th, 2026 10:53 am
Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk? - Aug 24th, 2026 10:51 am
Can Keros Therapeutics (KROS)’s $20M Takeda Pharmaceutical Company Limited (TAK) Milestone Unlock a Billion-Dollar Opportunity? - Aug 14th, 2026 5:37 pm
KROS Q2 Earnings Miss as Revenues Fall to Zero, Pipeline in Focus - Aug 4th, 2026 8:43 am
Keros Therapeutics Reports Second Quarter 2026 Financial Results - Aug 3rd, 2026 2:01 pm
Keros Therapeutics to Receive Development Milestone Payment from Partner Takeda - Jul 30th, 2026 2:01 pm
Keros Therapeutics Appoints Anne Prener to its Board of Directors - Jun 25th, 2026 2:01 pm
Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference - Jun 1st, 2026 2:01 pm
KROS Stock Guide to Rinvatercept in DMD and ALS for 2026 - May 22nd, 2026 9:03 am
Earnings Release: Here's Why Analysts Cut Their Keros Therapeutics, Inc. (NASDAQ:KROS) Price Target To US$21.20 - May 17th, 2026 7:36 am
Keros Therapeutics, Inc. (KROS) Reports Q1 Loss, Misses Revenue Estimates - May 14th, 2026 7:10 am
Keros Therapeutics Reports Recent First Quarter 2026 Financial Results - May 14th, 2026 6:00 am
Why Is Keros Therapeutics (KROS) Up 2.5% Since Last Earnings Report? - Apr 3rd, 2026 9:30 am